Companies such as Ionis Pharmaceuticals and Sarepta Therapeutics have developed several antisense therapies for Duchenne muscular dystrophy, transthyretin (TTR)-related hereditary amyloidosis, and spinal muscular atrophy (Table 2). The gene discussed is TTR; the disease is proximal spinal muscular atrophy.